Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

Abstract

AIM:

The feasibility of an alternating regimen of BIBF 1120, a potent, oral, triple angiokinase inhibitor, and afatinib (BIBW 2992), a potent ErbB family blocker, was explored in patients with advanced pretreated colorectal cancer (CRC).

PATIENTS AND METHODS:

Patients received repeated courses of alternating 7-day treatment periods, first with BIBF 1120 250 mg twice daily and then afatinib 50 mg once daily. The primary endpoint was the objective response rate; the incidence/severity of adverse events (AEs) and pharmacokinetics (PK) were determined.

RESULTS:

Forty-six patients (≥4 prior lines, most anti-VEGF and/or -EGFR pretreated) received BIBF 1120 and afatinib. No objective responses were observed; the best response was stable disease in 20 patients (43.5%). Seven patients (15.2%) remained progression-free for ≥16 weeks. Median progression-free survival was 1.9 months; median overall survival was 5.5 months. The most frequent drug-related AEs were diarrhoea (80.4%), asthenia (47.8%), nausea (43.5%) and rash (41.3%). PK assessments did not show obvious alterations for either drug.

CONCLUSION:

Weekly alternating administration of BIBF 1120 and afatinib is feasible; however, its efficacy was limited in this highly palliative patient population.

• Authors: Olivier Bouche, Frederique Maindrault-Goebel, Michel Ducreux, Gerard Lledo, Thierry Andre, Peter Stopfer, Nadia Amellal, Michael Merger, Aimery De Gramont
• Journal: Anticancer research (Anticancer Res) Vol. 31 Issue 6 Pg. 2271-81 (Jun 2011) ISSN: 1791-7530 [Electronic] Greece
• PMID: 21737652 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Indoles
• Quinazolines
• Afatinib
• nintedanib

Topics

• Afatinib
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, pharmacokinetics)
• Colorectal Neoplasms (drug therapy, metabolism)
• Disease-Free Survival
• Drug Administration Schedule
• Humans
• Indoles (administration & dosage, adverse effects, pharmacokinetics)
• Male
• Middle Aged
• Quinazolines (administration & dosage, adverse effects, pharmacokinetics)
• Survival Rate